Use of Accelerated Approval Pathway in Oncology

Vishal Bhatnagar, MD
Associate Director for Patient Outcomes
Oncology Center of Excellence, US FDA
November 8, 2022
Disclosures

• These slides represent current thinking in a rapidly evolving field of regulatory science
FDA’s Role in Cancer Drug and Biologic Development

• FDA is responsible for:
  • Assurance of the Safety, Efficacy and Security of:
    • Drug and Biological products
    • Medical Devices
    • Food supply
    • Cosmetics
    • Radiation products
  • Science and Collaboration

We do NOT regulate the cost of products
We do NOT regulate the practice of medicine
Striking the Balance

Flexible, Efficient, Interactive

CERTAINTY
DATA
Regulatory BURDEN

Less

More

Consistent, Thorough, Independent

“Too Cautious!
Stifling Innovation!
Reduce regulatory burden!”

“ Toxic deaths!
Delayed safety findings!
FDA asleep at the Wheel”
Accelerated Approval (AA) pathway

• Originally developed in 1992 to address HIV and AIDS crisis
• Intended for serious and life-threatening diseases
• Expedites access to drugs using trials that use a surrogate endpoint reasonably likely to predict benefit, OR an intermediate clinical endpoint other than irreversible morbidity or mortality
• May require post-approval studies to verify clinical benefit
• Dr. Pazdur: “...this program is for the patients!”
Advantages of AA in Oncology

• AA provides patients earlier access to new and practice-changing drugs
• AA may require sponsors to conduct confirmatory trials to verify the drug’s clinical benefit (typically required)
• AA is predominantly used in oncology, with cancer drugs accounting for about 85% of all AAs granted in the past decade (172 indications)
  • Clinical benefit has been verified in 50% of oncology AAs (86 indications)
  • Confirmatory trials ongoing in 38%, withdrawn indications 12%
• Median time to verification of clinical benefit and granting of traditional approval was 3.1 years (range, 0.5 to 17.6)
• Median time to withdrawal of an indication was 3.8 years (range, 1.3 to 12.5)
Response Rate is Becoming Increasingly Important
Formerly big populations are becoming very small subsets

Non-Small Cell Lung Cancer (NSCLC) 20 years ago

NSCLC Today

Jordan et al., Cancer Discov 7: 596-609, 2017
Precision Oncology – A Success Story

• Precision oncology (PO) has benefited from AA pathway → 42 AAs in precision oncology for solid tumors
  • 86% based on ORR
  • Median ORR 53%
  • No AAs in PO have been withdrawn
  • All PO AA indications granted before Nov 2018 have converted to traditional approval

• High ORRs, biomarker specific in early trials may make subsequent randomized trials difficult to conduct

Limitations of Single Arm Trials

• Rely on overall response rate
• Time-to-event endpoints (OS, PFS) uninterpretable
• Limited safety data
• Sponsors frequently delay initiation of confirmatory trials

• One randomized trial that could both support AA AND verify benefit.
  • AA could be granted on the basis of planned interim analysis of ORR
  • Traditional approval based on clinical benefit (OS) at the trial conclusion

Expanding Our Evidence Base in SATs

• Interpretation of PRO results supporting effectiveness (e.g. improvement in disease sx) can be challenging in SATs

• Safety data from single arm trials is usually limited

• Opportunity: to collect patient-reported tolerability in early phase trials
  • Collect 8-12 relevant treatment related symptoms using an item library
  • Overall side effect bother (e.g. FACT-GP5)
  • Physical/role function
  • Free text item where side effect profile is not well known

• Collection of PROs (tolerability) is feasible and informative in all trial designs, including SATs

Conclusions

• Single-arm trials and AA are a reality of the oncology drug development paradigm

• Use of the AA pathway in oncology has led to therapies being available many years earlier – e.g. precision oncology

• There are ways to use the AA pathway that do not rely on SATs.

• FDA and sponsors should agree in advance on trial designs, criteria for attaining AA, and how to confirm clinical benefit

• OCE is driving change in the current drug development paradigm: Project Confirm, Project FrontRunner
Acknowledgements and Additional Resources

• Richard Pazdur
• Paul Kluetz
• OCE staff
• Project Confirm - https://www.fda.gov/about-fda/oncology-center-excellence/project-confirm
• Project FrontRunner - https://www.fda.gov/about-fda/oncology-center-excellence/project-frontrunner